Jiang Hua*, Bo Song#, Peng Wang#, Qixiang Li, and Zonghai Li*#
*State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine
#CARsgen Therapeutics, Suite 401, Building 3, 466 Yindu Road, Xuhui District, Shanghai
There’s a growing interest in using CAR-T cell therapies for solid tumors as well as haematological malignancies. One such cancer subtype may be pancreatic cancer, which lacks curable treatment options, and is complicated by a hostile stroma microenvironment.
A potential new drug target which is highly expressed in pancreatic cancer is mesothelin. Mesothelin is a promising target for antitumour therapies including antibodies, vaccines, antibody-drug conjugates, as well as immunotherapies.
This poster details the development of a novel CAR-T cell therapy targeting mesothelin for pancreatic cancer treatment. Antitumour activity in vitro, using mesothelin-expressing cancer cells, as well in vivo, using a mesothelin-expressing patient-derived xenograft (PDX) model, is assessed.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2023-04-24
2021-10-27
landing_page
PDX/Databases